Undergraduate researcher (2012. 03-2013. 02)
MS (2013. 03 - 2015. 02)
Ph.D in Dept. of Bioenginering, Duke University (USA)
Current: Roche
8. Min, J., Song, E. K., Kim, H., Kim, K. T., Park, T. J.* and Kang, S.* A Recombinant Secondary Antibody Mimic as a Target-specific Signal Amplifier and an Antibody Immobilizer in Immunoassays. Sci. Rep. 2016, 6, 24159.
7. #Kim, H., #Kang, Y. J., Min, J., Choi, H. and Kang, S. Development of an Antibody-binding Modular Nanoplatform for Antibody-guided Targeted Cell Imaging and Delivery. RSC Adv. 2016, 6, 19208-19213.
# Equal contribution
6. Lee, J., Song, E., Bae, Y., Min, J., Rhee, H.-W., Park, T. J., Kim, M.,* and Kang, S.* An Enhanced Ascorbate Peroxidase 2/Antibody-Binding Domain Fusion Protein (APEX2-ABD) as a Recombinant Target-Specific Signal Amplifier. Chem. Comm. 2015, 51,10945-10948.
5. Min, J., Kim, S., Lee, J. and Kang, S. Lumazine Synthase Protein Cage Nanoparticles as Modular Delivery Platforms for Targeted Drug Delivery. RSC Advances, 2014, 4, 48596-48600.
4. Moon, H., Lee, J., Kim, H., Heo, S., Min, J. and Kang, S. Genetically Engineering Encapsulin Protein Cage Nanoparticle as a SCC-7 Cell Targeting Optical Nanoprobe. Biomater. Res., 2014, 18,21.
3. Moon, H., Lee, J., Min, J., and Kang, S. Developing Genetically Engineered Encapsulin Protein Cage Nanoparticles as Targeted Delivery Nanoplatforms. Biomacromolecules, 2014, 15, 3794-3801.
2. Min, J., Moon, H., Yang, H. J., Shin H. Hong, S. Y., and Kang, S. Development of P22 Viral Capsid Nanocomposites as Anti-cancer Drug, Bortezomib (BTZ), Delivery Nanoplatforms. Macromol. Biosci. 2014, 14, 557-564.
1. Min, J., Jung, H., Shin, H., Cho, G., Cho, H., and Kang, S., Implementation of P22 Viral Capsids as Intravascular MR T1 Contrast Conjugates via Site-selective Attachment of Gd (III)-chelating agents. Biomacromolecules, 2013, 14, 2332-2339.